Pooled efficacy and safety analysis of incobotulinumtoxinA for upper- and lower-limb spasticity in children with severe cerebral palsy (GMFCS levels IV–V)
Objective: To assess the efficacy and safety of incobotulinumtoxinA for lower-limb (LL) and upper-limb (UL) spasticity in children and adolescents with cerebral palsy (CP) and…Injections of incobotulinumtoxinA at intervals less than 10 weeks are effective and safe for cervical dystonia patients with inadequate benefit from standard injection intervals
Objective: To compare efficacy and safety of two injection schedules of incobotulinumtoxinA for treating cervical dystonia (CD). Background: In clinical practice, some CD patients receiving…A Double Blind, Placebo Controlled, Crossover Study of Incobotulinumtoxin-A in Musician’s Focal Hand Dystonia
Objective: To determine the safety and efficacy of incobotulinumtoxin-A (BoNT) in musician’s dystonia. Background: Few published trials of BoNT in upper limb task-specific dystonia are…Treatment of cervical dystonia using shorter incobotulinumtoxinA injection intervals improves patient-reported outcomes in those with inadequate benefits from standard intervals
Objective: To assess the impact of 2 different injection schedules of incobotulinumtoxinA on patient-reported assessments in cervical dystonia (CD). Background: There is individual variation in…Cost-Analysis of the Use of IncobotulinumtoxinA and AbobotulinumtoxinA for the Treatment of Post-Stroke Upper Limb Spasticity Based on Recommended Dosing for Muscles and Clinical Patterns
Objective: To carry out a cost-analysis based on the respective recommended dosing per muscle using IncobotulinumtoxinA (INCO) and AbobotulinumtoxinA (ABO) for the treatment of post-stroke…Cost-Utility Analysis of Flexible Intervals with IncobotulinumtoxinA Versus Fixed Dosing with OnabotulinumtoxinA in the Management of Cervical Dystonia and Blepharospasm in Major Canadian Markets
Objective: The aim was to carry out a cost-utility analysis for IncobotulinumtoxinA (INCO) administered with flexible treatment intervals compared to onabotulinumtoxinA (ONA) administered with fixed…IncobotulinumtoxinA is effective, long lasting and well tolerated treatment of hemifacial spasm
Objective: Hemifacial spasm (HFS) is a common movement disorder characterized by involuntary contractions of the muscles innervated by facial nerve. Background: To evaluate the effect…Development of a patient-reported Botulinum Toxin Response Scale (BTRS) for neurological disorders: a feasibility study.
Objective: To assess the feasibility of developing a patient-reported Botulinum Toxin Response Scale (BTRS) for different neurological conditions. Background: Botulinum toxin (BoNT) is a highly…Tardive Cervical Dystonia: Treatment with Botulinum: Treatment with Botulinum Toxin Guided by Electromyography
Objective: To describe the use of botulinum toxin in the treatment of tardive dystonia. Background: Tardive dystonia (TD) was recognized as a complication of dopamine…Efficacy of incobotulinumtoxinA in patients with sialorrhea, as assessed using the modified Radboud Oral Motor Inventory for Parkinson’s disease (mROMP): Results of the SIAXI study
Objective: The pivotal double-blind, randomised Phase III SIAXI study (NCT02091739), assessed the efficacy and safety of incobotulinumtoxinA 75 or 100 U for sialorrhea. Co-primary endpoints…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.